GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Pozycja w akcjach
#3633
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Cena akcji
$27.56
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$4.67B
Zmiana (1 dzień)
-2.65%
Zmiana (1 rok)
-11.79%
Kraj
IN
Handel GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategoria
Healthcare
EPS dla GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
EPS na dzień June 2026 TTM: $0.70
Według najnowszych raportów finansowych i ceny akcji firmy GlaxoSmithKline Pharmaceuticals Limited, obecny EPS (TTM) wynosi $0.70. Na koniec roku 2024 firma miała EPS w wysokości $0.42, spadek w porównaniu do do EPS z roku 2023, który wynosił $0.44.
Historia EPS dla GlaxoSmithKline Pharmaceuticals Limited od 2004 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $0.70 | 8.72% |
| 2025 | $0.64 | 53.29% |
| 2024 | $0.42 | -4.31% |
| 2023 | $0.44 | 55.78% |
| 2022 | $0.28 | 20.93% |
| 2021 | $0.23 | 217.40% |
| 2020 | $0.07 | -80.72% |
| 2019 | $0.38 | 19.09% |
| 2018 | $0.32 | 3.69% |
| 2017 | $0.31 | -8.50% |
| 2016 | $0.34 | -7.07% |
| 2015 | $0.36 | -0.91% |
| 2013 | $0.36 | -39.74% |
| 2012 | $0.60 | 26.71% |
| 2011 | $0.48 | -35.63% |
| 2010 | $0.74 | 14.81% |
| 2009 | $0.64 | -10.33% |
| 2008 | $0.72 | -12.43% |
| 2007 | $0.82 | 11.92% |
| 2006 | $0.73 | 11.91% |
| 2005 | $0.66 | 47.32% |
| 2004 | $0.45 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $29.89 | 4,195.77% |
US
|
|
| $6.60 | 848.55% |
US
|
|
| $3.55 | 410.20% |
US
|
|
| $1.26 | 81.09% |
US
|
|
| $20.39 | 2,830.30% |
CH
|
